- Home
- OCEAW vs NAVI Comparison
OCEAW vs NAVI Comparison
Compare OCEAW & NAVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCEAW
- NAVI
- Stock Information
- Founded
- OCEAW N/A
- NAVI 1973
- Country
- OCEAW United States
- NAVI United States
- Employees
- OCEAW 7
- NAVI N/A
- Industry
- OCEAW Biotechnology: Pharmaceutical Preparations
- NAVI Investment Bankers/Brokers/Service
- Sector
- OCEAW Health Care
- NAVI Finance
- Exchange
- OCEAW Nasdaq
- NAVI Nasdaq
- Market Cap
- OCEAW N/A
- NAVI N/A
- IPO Year
- OCEAW 2021
- NAVI N/A
- Fundamental
- Price
- OCEAW $0.03
- NAVI $12.63
- Analyst Decision
- OCEAW
- NAVI Hold
- Analyst Count
- OCEAW 0
- NAVI 7
- Target Price
- OCEAW N/A
- NAVI $13.79
- AVG Volume (30 Days)
- OCEAW N/A
- NAVI 763.0K
- Earning Date
- OCEAW N/A
- NAVI 04-23-2025
- Dividend Yield
- OCEAW N/A
- NAVI 5.06%
- EPS Growth
- OCEAW N/A
- NAVI N/A
- EPS
- OCEAW N/A
- NAVI 1.18
- Revenue
- OCEAW N/A
- NAVI $848,000,000.00
- Revenue This Year
- OCEAW N/A
- NAVI N/A
- Revenue Next Year
- OCEAW N/A
- NAVI $0.88
- P/E Ratio
- OCEAW N/A
- NAVI $10.72
- Revenue Growth
- OCEAW N/A
- NAVI N/A
- 52 Week Low
- OCEAW N/A
- NAVI $12.51
- 52 Week High
- OCEAW N/A
- NAVI $17.56
- Technical
- Relative Strength Index (RSI)
- OCEAW N/A
- NAVI 35.11
- Support Level
- OCEAW N/A
- NAVI $13.23
- Resistance Level
- OCEAW N/A
- NAVI $13.41
- Average True Range (ATR)
- OCEAW 0.00
- NAVI 0.36
- MACD
- OCEAW 0.00
- NAVI -0.06
- Stochastic Oscillator
- OCEAW 0.00
- NAVI 9.96
About OCEAW Ocean Biomediacal Inc.
Ocean Biomedical Inc is a biopharmaceutical company that is focused on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.